INS and Alzheimer disease: Then, an independent group conducted an emulated target trial (ETT) over a 3-year follow-up on the same database in 1+ million patients with T2DM and found that semaglutide was associated with reduced risk of AD diagnosis specifically when compared with insulin (HR 0.33; 95% CI 0.20, 0.51) and other GLP-1RAs (HR 0.59; 95% CI 0.37, 0.95).58